Qianru Hong

Qianru Hong is an associate in O'Melveny's Shanghai office. She has participated in projects covering mergers and acquisitions, foreign direct investment, private equity and venture capital investments, capital markets, and other financing matters, investigations and compliance, intellectual property, employment, and general corporate matters, in industries spanning internet, telecommunications, e-commerce finance, media, pharmaceuticals and energy, among others.

Prior to joining the firm, Qianru interned with the Shanghai offices of a US law firm, a Hong Kong law firm and a Chinese domestic law firm.

• Acotec Scientific in its approximately US$520 million voluntary partial offer by Boston Scientific
• Represented a buyer consortium led by Fang Holdings (OTC: SFUNY) in going private transaction involving China Index Holdings (NASDAQ: CIH) valued at approximately US$92 million
• Belite Bio, Inc (NASDAQ: BLTE) in its US$36 million IPO and listing on NASDAQ
• OrbusNeich Medical Group in its US$200 million Series A and A-2 Fundraising Rounds
• Brii Biosciences Limited in its US$318 million IPO and listing on the Hong Kong Stock Exchange
• BNP Paribas, China Construction Bank International, Industrial and Commercial Bank of China International and other underwriters in the spin-off and approximately US$126 million listing of Central China Management Company Limited on the Hong Kong Stock Exchange
• TTM technologies (NASDAQ: TTMI), a leading global printed circuit board (PCB) manufacturer, on the US$660 million divestiture of its four China manufacturing plants comprising substantially all of the assets of its Mobility business, to AKMMeadville Electronics (Xiamen) Co., Ltd.
• a US listed company in its purchase of the China LED business of another US listed company for up to US$300 million
• JACOBIO Pharmaceuticals Group Co., Ltd. in its US$174 million IPO and listing on the Hong Kong Stock Exchange
• RemeGen Co., Ltd. in its US$515 million IPO and listing on the Hong Kong Stock Exchange
• a buyer consortium led by Yunfeng Capital, TF Capital, GIC and management in connection with the acquisition of Cellular Biomedicine Group in a "going private" transaction valued at approximately US$380 million
• buyer group in the going private transaction of SORL Auto Parts
• buyer group in the going private transaction of China XD Plastics
• a biosimilar company with operations in China and Taiwan in its spin-off and follow-on financing
• a private equity fund in its US$756 million acquisition of three officer towers in China
• various venture capital deals including representations of internationally recognized venture capital funds and start-up or pre-IPO companies
• a U.S. public REIT in setting up an equity investment fund in Shanghai
• a U.S. coal technology company's financing and its foreign direct investment in China
• an Asian private equity fund in its acquisition of office buildings in China
• a biopharmaceutical company's spin-off and follow-up financing
• a Swedish security lock company in its acquisition of a well-known Chinese fingerprint lock company
• a U.S. floor manufacturer in its acquisition of its Chinese partners interest in their China joint venture
• small-loan companies in Chongqing in their loan transactions and with respect to PRC finance laws and regulations
• a leading high-tech company in its dismantling of its red-chip structure and its proposed IPO in China
• several matters representing multinational corporations establishing joint ventures, wholly foreign owned enterprises, representative offices and branch companies in China
• general corporate matters for a number of multinational companies' subsidiaries in China, including regulatory compliance and employment related advice